Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypericum vs Fluoxetine in Adolescent Depression
NCT00557427Phase 4Terminated
- Sponsor
- Rafa Laboratories
- Start
- Jan 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of St. John's wort extract Ze 117 in major depressive disorder (MDD) (2 arms), sponsored by Rafa Laboratories. Primary endpoint: Rate of clinical response (CDRS-R < 28) at 8 weeks. Started Jan 2009; status: terminated.
02
Drugs
St. John's wort extract Ze 117
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00557427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557427.